What is the efficacy of zanamivir in the treatment of influenza?

Updated: Aug 07, 2020
  • Author: Hien H Nguyen, MD, MS; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

In a study of 837 relatives of family members infected with influenza, 20% of those treated with placebo became ill, compared with only 4% of those who received prophylactic zanamivir. [89] In addition, this study provided treatment to the index case family member, resulting in a 2.5-day reduction in illness as compared with placebo. Recombinant DNA viral sequences were performed in this study, and no resistant influenza strains developed.

In a placebo-controlled study of 445 patients by the Management of Influenza in the Southern Hemisphere Trialists (MIST) group 1, zanamivir reduced the duration and severity of illness. [90] Zanamivir was administered within 36 hours of symptom onset. The duration of influenza was reduced by 1.5 days in normal-risk groups and 2.5 days in high-risk groups. A significant decrease in the severity of illness in patients treated with zanamivir allowed them to resume normal activities much sooner.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!